Equities
Health CarePharmaceuticals & Biotechnology
  • Price (DKK)348.90
  • Today's Change-7.90 / -2.21%
  • Shares traded443.37k
  • 1 Year change+9.54%
  • Beta0.7218
Data delayed at least 15 minutes, as of Jan 15 2021 15:59 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

  • Revenue in DKK (TTM)14.30bn
  • Net income in DKK3.09bn
  • Incorporated2000
  • Employees6.18k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NZYM B:CPH since
announced
Transaction
value
Microbiome Labs Physicians Exclusive LLCAnnounced18 Dec 202018 Dec 2020Announced1.84%250.00m
Precisionbiotics LtdDeal completed25 Jun 202025 Jun 2020Deal completed-7.75%90.00m
Data delayed at least 15 minutes, as of Jan 15 2021 15:59 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Lanxess AG44.56bn6.68bn41.54bn14.35k6.151.673.710.932310.399.7368.9638.250.67743.517.19418,764.0010.002.1411.732.8925.1124.4214.762.642.357.450.472542.88-0.3224-3.2134.2140.25-3.7213.70
Uralkaliy PAO14.45bn1.04bn42.65bn20.38k12.251.2815.952.959.729.72135.7593.340.30593.685.628,459,572.002.198.382.6811.5471.4676.187.1726.411.441.730.75250.003.825.59980.62--11.78--
Clariant AG28.44bn1.02bn44.34bn17.01k43.092.5813.591.560.44850.594112.477.480.52574.096.44238,924.702.222.322.983.3531.9130.764.233.451.113.660.4718191.31-0.1135-6.38-129.08---2.2049.63
Johnson Matthey PLC123.32bn861.87m44.50bn13.94k51.531.9719.620.36090.53330.533376.3513.961.997.806.751,057,321.001.396.572.489.666.087.770.69892.870.78884.560.380860.0935.667.70-38.26-9.8715.87-5.03
Imcd NV20.11bn801.99m44.94bn3.05k51.616.5733.442.242.052.0551.4916.141.265.915.85903,602.805.035.147.266.8420.0519.473.994.110.82936.620.507641.4213.0514.647.9440.2431.0730.78
Arkema SA59.16bn2.60bn55.17bn20.50k22.101.417.310.93264.374.3799.3568.440.74995.886.40401,961.303.475.454.286.7519.6621.564.636.151.745.600.34833.05-0.88487.98-27.1524.076.343.53
Chr Hansen Holding A/S7.39bn1.65bn74.36bn3.60k45.1710.7330.3010.0612.4913.2955.9452.570.37312.636.592,052,683.008.3411.4412.1414.1459.1356.7222.3621.870.212918.540.654759.993.482.471.057.3411.00--
Yara International ASA71.13bn3.96bn74.63bn16.03k18.911.497.751.0520.4620.46366.62260.190.7133.697.486,167,240.003.953.984.895.0030.5525.785.544.861.464.110.3286108.71-0.5415-3.13276.73-13.11-0.864112.77
Brenntag AG89.50bn3.46bn76.89bn17.11k22.222.9613.470.85923.013.0177.9622.581.418.126.71687,771.605.495.527.397.5622.8821.503.903.491.3710.890.409340.282.175.061.266.5814.656.79
Novozymes A/S14.30bn3.09bn80.69bn6.18k31.899.0218.985.6410.9410.9450.5838.690.70992.365.042,451,054.0015.3616.3720.1821.1856.0957.4821.6421.520.9465--0.335542.19-0.11122.90-2.234.546.6411.84
Umicore SA147.82bn1.71bn83.22bn13.74k47.654.1918.860.5630.95270.952782.1710.852.838.1515.251,406,503.003.434.885.518.125.337.361.211.910.87595.520.485942.8727.4716.56-9.2113.0124.87-6.89
OMV AG131.43bn-1.99bn89.64bn19.23k--0.97673.680.682-0.8164-0.816453.5937.700.43426.947.16890,299.80-0.02462.09-0.03583.1032.8724.83-0.05663.281.4647.320.3824114.832.32-8.1616.6943.27-10.866.96
Evonik Industries AG91.28bn4.55bn93.42bn32.82k20.571.518.601.021.311.1926.2417.800.56194.377.90378,465.902.884.173.445.0527.8231.015.125.961.149.980.355868.57-1.200.2949.775.47-4.282.83
Data as of Jan 15 2021. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

21.79%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 201914.17m6.13%
Baillie Gifford & Co.as of 08 Jan 20216.52m2.82%
MFS International (UK) Ltd.as of 31 Oct 20206.42m2.78%
The Vanguard Group, Inc.as of 30 Nov 20205.83m2.52%
Canada Pension Plan Investment Boardas of 31 Mar 20203.39m1.47%
BlackRock Fund Advisorsas of 07 Jan 20213.24m1.40%
Harding Loevner LPas of 30 Nov 20202.94m1.27%
Walter Scott & Partners Ltd.as of 30 Nov 20202.79m1.21%
Impax Asset Management Ltd.as of 30 Nov 20202.73m1.18%
NNIP Advisors BVas of 31 Mar 20202.35m1.02%
More ▼
Data from 31 Dec 2019 - 30 Nov 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.